Upon joining the trial, the patient will be required to provide a signed informed consent. This confirms understanding and agreement to participate in the study.

Eligibility is confirmed through a PCR/NAAT test that verifies a monkeypox infection and the presence of active skin or mucosal lesions.

The patient will be randomly assigned to either the treatment group or the control group. This process is called randomization and ensures that each participant has an equal chance of receiving the tecovirimat treatment or a placebo.

If assigned to the treatment group, the patient will receive tecovirimat SIGA 200 mg hard capsules. The medication is taken orally.

The dosage and frequency of administration will be provided by the study team and must be followed as instructed.

The patient’s progress will be monitored through regular assessments. These include checking the status of lesions on days 7, 14, 21, and 28.

The primary goal is to observe the time it takes for all lesions to completely heal, which is assessed at day 28.

The patient will self-assess symptoms such as fatigue, nausea, and fever. These symptoms will be tracked throughout the trial.

The occurrence of a negative monkeypox PCR test will be checked on days 7, 14, and 28.

The patient’s quality of life will be evaluated using the Dermatology Quality of Life Index on days 7, 14, 28, and 90.

This assessment helps understand the impact of the treatment on daily life.

On day 90, the persistence of scars and skin discoloration will be assessed.

The study will also evaluate any adverse events or serious adverse events that may have occurred during the trial.